Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRD119
MIFTS: 66

Cardiac Arrest

Categories: Blood diseases, Cardiovascular diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Cardiac Arrest

About this section

MalaCards integrated aliases for Cardiac Arrest:

Name: Cardiac Arrest 12 77 30 56 6 44 15 17 74
Cardiopulmonary Arrest 12 56 74
Circulatory Arrest 12 15 74
Heart Arrest 45

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:0060319
ICD9CM 36 427.5
MeSH 45 D006323
SNOMED-CT 69 30298009
ICD10 34 I46 I46.0
Sources

Summaries for Cardiac Arrest

About this section
MedlinePlus : 44 The heart has an internal electrical system that controls the rhythm of the heartbeat. Problems can cause abnormal heart rhythms, called arrhythmias. There are many types of arrhythmia. During an arrhythmia, the heart can beat too fast, too slow, or it can stop beating. Sudden cardiac arrest (SCA) occurs when the heart develops an arrhythmia that causes it to stop beating. This is different than a heart attack, where the heart usually continues to beat but blood flow to the heart is blocked. There are many possible causes of SCA. They include coronary heart disease, physical stress, and some inherited disorders. Sometimes there is no known cause for the SCA. Without medical attention, the person will die within a few minutes. People are less likely to die if they have early defibrillation. Defibrillation sends an electric shock to restore the heart rhythm to normal. You should give cardiopulmonary resuscitation (CPR) to a person having SCA until defibrillation can be done. If you have had an SCA, an implantable cardiac defibrillator (ICD) reduces the chance of dying from a second SCA. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Cardiac Arrest, also known as cardiopulmonary arrest, is related to ventricular fibrillation, paroxysmal familial, 1 and arrhythmogenic right ventricular cardiomyopathy, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Cardiac Arrest is PLN (Phospholamban), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Aldosterone synthesis and secretion. The drugs Clonazepam and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and kidney, and related phenotypes are behavior/neurological and cardiovascular system

Disease Ontology : 12 A congestive heart failure characterized by a sudden stop in effective blood circulation due to the failure of the heart to contract effectively or at all.

Wikipedia : 77 Cardiac arrest is a sudden loss of blood flow resulting from the failure of the heart to effectively... more...

Sources

Related Diseases for Cardiac Arrest

About this section

Diseases in the Cardiac Arrest family:

Post-Cardiac Arrest Syndrome

Diseases related to Cardiac Arrest via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 490)
# Related Disease Score Top Affiliating Genes
1 ventricular fibrillation, paroxysmal familial, 1 32.7 DSP KCNQ1 RYR2 SCN5A TNNT2
2 arrhythmogenic right ventricular cardiomyopathy 32.6 DSP PLN RYR2 SCN5A
3 cardiac conduction defect 32.2 DSP KCNQ1 MYBPC3 PLN RYR2 SCN5A
4 myocardial infarction 32.1 ACE ALB CKB S100B TNNT2
5 long qt syndrome 1 31.9 CALM1 CALM3 CASQ2 DSP KCNQ1 RYR2
6 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 31.6 CALM1 CASQ2 DSP KCNQ1 RYR2 SCN5A
7 long qt syndrome 30.5 CALM1 CALM3 KCNQ1 MYBPC3 RYR2 SCN5A
8 cardiac arrhythmia 30.5 KCNQ1 RYR2 SCN5A
9 atrial standstill 1 30.5 ACE DSP MYBPC3 PLN SCN5A SLC25A20
10 atrial fibrillation 30.4 ACE KCNQ1 MYBPC3 RYR2 SCN5A
11 hypertrophic cardiomyopathy 30.3 ACE DSP MYBPC3 PLN RYR2 SCN5A
12 catecholaminergic polymorphic ventricular tachycardia 30.3 CALM1 CALM3 CASQ2 DSP MYBPC3 RYR2
13 neonatal hypoxic and ischemic brain injury 30.3 CKB ENO2
14 long qt syndrome 15 30.2 CALM1 CALM3
15 heart disease 29.9 ACE ALB DSP KCNQ1 MYBPC3 RYR2
16 middle cerebral artery infarction 29.9 ENO2 S100B
17 left ventricular noncompaction 29.7 DSP KCNQ1 MYBPC3 RYR2 SCN5A TNNT2
18 dilated cardiomyopathy 29.2 ACE ALB DSP KCNQ1 MYBPC3 PLN
19 post-cardiac arrest syndrome 12.5
20 jervell and lange-nielsen syndrome 1 11.5
21 hypoxia 11.4
22 hypokalemia 11.4
23 myocarditis 11.4
24 orthostatic intolerance 11.4
25 pulmonary edema 11.4
26 cerebral hypoxia 11.4
27 wolff-parkinson-white syndrome 11.4
28 eclampsia 11.4
29 sudden cardiac failure, infantile 11.4
30 sudden cardiac failure, alcohol-induced 11.4
31 cyanide poisoning 11.4
32 cardiomyopathy, infantile histiocytoid 11.3
33 ventricular tachycardia, catecholaminergic polymorphic, 3 11.2
34 coronary artery dissection, spontaneous 11.0
35 pseudohyperkalemia, familial, 2, due to red cell leak 11.0
36 ventricular tachycardia, catecholaminergic polymorphic, 2 11.0
37 ventricular tachycardia, catecholaminergic polymorphic, 4 11.0
38 ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness 11.0
39 familial isolated arrhythmogenic ventricular dysplasia, right dominant form 10.5 DSP RYR2
40 familial isolated arrhythmogenic ventricular dysplasia, biventricular form 10.5 DSP RYR2
41 familial isolated arrhythmogenic ventricular dysplasia, left dominant form 10.5 DSP RYR2
42 cardiogenic shock 10.5
43 ocular motor apraxia 10.5
44 pulmonary embolism 10.5
45 intracranial cysts 10.5 ENO2 S100B
46 otomycosis 10.5 CALM1 CALM3
47 ischemia 10.5
48 bednar tumor 10.5 ENO2 S100B
49 external ear disease 10.5 CALM1 CALM3
50 eosinophilia-myalgia syndrome 10.4

Comorbidity relations with Cardiac Arrest via Phenotypic Disease Network (PDN): (show all 33)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Aortic Aneurysm Aortic Valve Disease 1
Bronchitis Cardiogenic Shock
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Disseminated Intravascular Coagulation Familial Atrial Fibrillation
First-Degree Atrioventricular Block Generalized Atherosclerosis
Heart Disease Hypertension, Essential
Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome Intermediate Coronary Syndrome
Ischemic Heart Disease Kidney Disease
Mitral Valve Disease Ocular Motor Apraxia
Peripheral Vascular Disease Progressive Familial Heart Block, Type Ia
Protein-Energy Malnutrition Pulmonary Hypertension, Primary, 1
Respiratory Failure Sinoatrial Node Disease
Third-Degree Atrioventricular Block Tricuspid Valve Disease
Ventricular Fibrillation, Paroxysmal Familial, 1

Graphical network of the top 20 diseases related to Cardiac Arrest:



Diseases related to Cardiac Arrest
Sources

Symptoms & Phenotypes for Cardiac Arrest

About this section

UMLS symptoms related to Cardiac Arrest:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Cardiac Arrest:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 ACE AVP CKB CYCS ENO2 KCNQ1
2 cardiovascular system MP:0005385 9.85 ACE CASQ2 CYCS DSP KCNQ1 MYBPC3
3 growth/size/body region MP:0005378 9.7 ACE CASQ2 CKB CYCS DSP ENO2
4 muscle MP:0005369 9.28 ALB CASQ2 DSP KCNQ1 MYBPC3 RYR2
Sources

Drugs & Therapeutics for Cardiac Arrest

About this section

Drugs for Cardiac Arrest (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 782)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
2
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
3
Lorazepam Approved Phase 4,Not Applicable 846-49-1 3958
4
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
5
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
6
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
7
Ticagrelor Approved Phase 4 274693-27-5 9871419
8
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
9
Midazolam Approved, Illicit Phase 4,Phase 3,Not Applicable 59467-70-8 4192
10
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 113775-47-6 5311068 68602
11
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
12
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
13
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
14
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 62-31-7, 51-61-6 681
15
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
16
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
17
Cisatracurium Approved Phase 4 96946-41-7
18
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
19
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137-58-6 3676
20
Ketamine Approved, Vet_approved Phase 4,Not Applicable 6740-88-1 3821
21
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
22
Nitric Oxide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 10102-43-9 145068
23
Mannitol Approved, Investigational Phase 4,Phase 2,Not Applicable 69-65-8 6251 453
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
25
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
26
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-56-6 53477758 439302
27
Dobutamine Approved Phase 4,Phase 3,Not Applicable 34368-04-2 36811
28
Misoprostol Approved Phase 4,Phase 1 59122-46-2 5282381
29 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 7681-49-4
30
Nitroprusside Approved, Investigational Phase 4,Phase 3 15078-28-1 11963622
31
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-41-2 439260
32
Oxymetazoline Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1491-59-4 4636
33
Phenylephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 59-42-7 6041
34
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613
35
Clopidogrel Approved Phase 4,Not Applicable 120202-66-6, 113665-84-2 60606
36
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 16590-41-3 5360515
37
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
38
Nifedipine Approved Phase 4,Phase 2 21829-25-4 4485
39
Ritodrine Approved, Investigational Phase 4 26652-09-5 33572
40
Atropine Approved, Vet_approved Phase 4,Phase 2 5908-99-6, 51-55-8 174174
41
Meperidine Approved Phase 4 57-42-1 4058
42
Atorvastatin Approved Phase 4,Phase 2,Phase 3,Phase 1 134523-00-5 60823
43
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
44
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
45
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
46
Ofloxacin Approved Phase 4 82419-36-1 4583
47
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3 28014-46-2
48
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
49
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-28-2 5757
50
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946

Interventional clinical trials:

(show top 50) (show all 1748)
# Name Status NCT ID Phase Drugs
1 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
2 Hyperinvasive Approach in Cardiac Arrest Unknown status NCT01511666 Phase 4
3 Therapeutic Hypothermia With Propofol in Survival and Neurological Prognoses After Cardiac Arrest Unknown status NCT02367755 Phase 4 Propofol;Lorazepam
4 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4 sodium bicarbonate
5 Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome Unknown status NCT02341729 Phase 4 ticagrelor
6 Early Feeding Following Ligation of Acute Bleeding Varices Unknown status NCT01287702 Phase 4
7 Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
8 Effects of Preconditioning With Sevoflurane During Organ Procurement From Brain Dead Donors: Impact on Early Function of Liver Allografts Unknown status NCT02341833 Phase 4 Sevoflurane
9 CERAMENTâ„¢|G - Bone Healing and Re-infection Prophylaxis Unknown status NCT02128256 Phase 4
10 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
11 Role of FSHR Polymorphism p.N680S in the Therapy With FSH in Patients Who Underwent Varicocele Surgery Unknown status NCT02719093 Phase 4 recombinant FSH
12 Safety and Efficacy of Intranasal Dexmedetomidine Unknown status NCT02985697 Phase 4 Dexmedetomidine;Midazolam Hydrochloride;Nitrous Oxide
13 Assess the Penumbra System in the Treatment of Acute Stroke Unknown status NCT01429350 Phase 4 intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
14 Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism Unknown status NCT02029456 Phase 4 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
15 Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery Unknown status NCT02672813 Phase 4
16 The Effect of Chest Tubes Using Active Clearance Technology® on the Incidence of Postoperative Atrial Fibrillation Unknown status NCT02808897 Phase 4
17 Prophylactic Antibiotics in Comatose Survivors of Out-of-hospital Cardiac Arrest Completed NCT02899507 Phase 4 Amoxicillin-Clavulanic acid
18 Continuous Chest Compressions vs AHA Standard CPR of 30:2 Completed NCT01372748 Phase 4
19 Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest Completed NCT00127907 Phase 4 epinephrine (1 mg/1 mL);arginine-vasopressin (40 UI/2 mL)
20 Intraosseous vs Intravenous Access for Cardiac Arrest Treatment Completed NCT02088736 Phase 4
21 Comparing Therapeutic Hypothermia Using External and Internal Cooling for Post-Cardiac Arrest Patients Completed NCT00827957 Phase 4
22 Clinical and Economical Interest of Endovascular Cooling in the Management of Cardiac Arrest (ICEREA Study) Completed NCT00392639 Phase 4
23 Trial of Different Hypothermia Temperatures in Patients Recovered From Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
24 Antiplatelet Therapy After Cardiac Arrest Completed NCT02224274 Phase 4 Clopidogrel;Ticagrelor
25 COOL-Trial: Outcome With Invasive and Non-invasive Cooling After Cardiac Arrest Completed NCT00843297 Phase 4
26 Prevention of Acute Kidney Injury by Erythropoietin in Thoracic Aorta Surgery With Hypothermic Cardiac Arrest Completed NCT01369732 Phase 4 recombinant human erythropoietin;saline
27 Cardiopulmonary Resuscitation Witnessing by a Relative Completed NCT01009606 Phase 4
28 Beating Versus Arrested Heart for Mitral Valve Replacement Completed NCT01641614 Phase 4
29 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
30 Quick ICD Study: Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary ? Completed NCT00180362 Phase 4
31 Transthoracic Incremental Monophasic Versus Biphasic by Emergency Responders (TIMBER) Completed NCT00101881 Phase 4
32 Trial of IV NTG for CD After Second Stage Arrest for the Prevention of Uterine Extension Completed NCT02265965 Phase 4 intravenous nitroglycerin
33 The Effect of Silver Diamine Fluoride (SDF) on Bacteria Involved in Root or Cervical Carious Lesions Completed NCT02953886 Phase 4
34 Randomized Trial of Pulsatile vs Non Pulsatile Perfusion on Short Term Changes in Kidney Function Using an Intra-Aortic Ballooon Pump During Cardioplegic Arrest in Patients Undergoing Myocardial Reperfusion Completed NCT00454428 Phase 4
35 Comparative Study Between Nifedipine and Ritodrine as Maintenance Tocolytic Therapy in Preterm Labor Completed NCT03040752 Phase 4 Nifedipine 20 Mg;Ritodrine Oral Tablet
36 ISSUE3: International Study on Syncope of Uncertain Etiology 3 Completed NCT00359203 Phase 4
37 Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy Completed NCT00575523 Phase 4 Atropine;Placebo
38 The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial Completed NCT00430989 Phase 4 Nitrous Oxide;Nitrous Oxide
39 Study of the Effectiveness of Administration of Meperidine on the Length of Active Phase of Labor in Women Completed NCT01555671 Phase 4 Placebo;Meperidine
40 Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD Completed NCT00159835 Phase 4 atorvastatin;simvastatin
41 Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia Completed NCT00665327 Phase 4 Avelox (Moxifloxacin, BAY12-8039);Levofloxacin
42 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated Completed NCT01157351 Phase 4 paliperidone;risperidone;haloperidole;perphenazine;aripiprazole;quetiapine;paliperidone palmitate;olanzapine
43 Out-of-Hospital Intubation With Metal Single Use Laryngoscope Blades Completed NCT00644722 Phase 4
44 Fluvastatin in the Therapy of Acute Coronary Syndrome Completed NCT00171275 Phase 4 Fluvastatin
45 Heart Outcomes Prevention Evaluation-3 Completed NCT00468923 Phase 4 Candesartan/HCT;Rosuvastatin
46 IRIS : Use of Implantable Defibrillator in High-risk Patients Early After Acute Myocardial Infarction Completed NCT00157768 Phase 4
47 Preventive and Therapeutic Proximal Sealants Completed NCT02338180 Phase 4
48 Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke Completed NCT00147602 Phase 4 atorvastatin
49 Evaluation of Statin Mechanism Preventing Cardiovascular Disease by Post-hoc Analysis of Treating to New Targets Study Completed NCT03073863 Phase 4 Atorvastatin
50 CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events Completed NCT00327418 Phase 4 Atorvastatin

Search NIH Clinical Center for Cardiac Arrest

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: heart arrest

Sources

Genetic Tests for Cardiac Arrest

About this section

Genetic tests related to Cardiac Arrest:

# Genetic test Affiliating Genes
1 Cardiac Arrest 30
Sources

Anatomical Context for Cardiac Arrest

About this section

MalaCards organs/tissues related to Cardiac Arrest:

42
Heart, Brain, Kidney, Breast, Lung, Testes, Bone
Sources

Publications for Cardiac Arrest

About this section

Articles related to Cardiac Arrest:

(show top 50) (show all 4612)
# Title Authors Year
1
Clinicopathological features of TAFRO syndrome complicated by acquired hemophilia A and development of cardiopulmonary arrest that were successfully treated with VA-ECMO and tocilizumab. ( 30680669 )
2019
2
Impella use in acute myocardial infarction complicated by cardiogenic shock and cardiac arrest : Analysis of 10 years registry data. ( 31009694 )
2019
3
Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ( 30799546 )
2019
4
Predictors of Successful Weaning From Veno-Arterial Extracorporeal Membrane Oxygenation After Coronary Revascularization for Acute Myocardial Infarction Complicated by Cardiac Arrest: A Retrospective Multicenter Study. ( 30080744 )
2019
5
Cardiac arrest as an age-dependent prognosticator for long-term mortality after acute myocardial infarction: the potential impact of infarction size. ( 29856229 )
2019
6
The acute respiratory distress syndrome after out-of-hospital cardiac arrest: Incidence, risk factors, and outcomes. ( 30654012 )
2019
7
Depression and anxiety in relatives of out-of-hospital cardiac arrest patients: Results of a prospective observational study. ( 30745287 )
2019
8
Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. ( 30874766 )
2019
9
Assessing brain injury after cardiac arrest, towards a quantitative approach. ( 31022084 )
2019
10
Reply to: Optic nerve sheath diameter measurement in hypoxic ischaemic brain injury after cardiac arrest. ( 30878373 )
2019
11
Optic nerve sheath diameter measurement in hypoxic ischaemic brain injury after cardiac arrest. ( 30878376 )
2019
12
The Burden of Brain Hypoxia and Optimal Mean Arterial Pressure in Patients With Hypoxic Ischemic Brain Injury After Cardiac Arrest. ( 30889022 )
2019
13
A comparison of non-invasive versus invasive measures of intracranial pressure in hypoxic ischaemic brain injury after cardiac arrest. ( 30629992 )
2019
14
Prevalence of spontaneous type I ECG pattern, syncope, and other risk markers in sudden cardiac arrest survivors with Brugada syndrome. ( 30569504 )
2019
15
Corrigendum to "Time of on-scene resuscitation in out of-hospital cardiac arrest patients transported without return of spontaneous circulation" [Resuscitation 138 (2019) 235-242]. ( 31100212 )
2019
16
Disseminated intravascular coagulation in cardiac arrest and resuscitation. ( 31102491 )
2019
17
Cheap, fast, or reliable: Picking two in prognostication after out of hospital cardiac arrest (OHCA). ( 31102576 )
2019
18
Comparison of Long-Term Survival Following Sudden Cardiac Arrest in Men Versus Women. ( 31103131 )
2019
19
Brain Diffusion Imaging Findings May Predict Clinical Outcome after Cardiac Arrest. ( 31107566 )
2019
20
Response by DeFilippis et al to Letter Regarding Article, "Long-Term Outcomes After Out-of-Hospital Cardiac Arrest in Young Patients With Myocardial Infarction: Partners YOUNG-MI Registry". ( 31107615 )
2019
21
Letter by Karam et al Regarding Article, "Long-Term Outcomes After Out-of-Hospital Cardiac Arrest in Young Patients With Myocardial Infarction: Partners YOUNG-MI Registry". ( 31107622 )
2019
22
Review: In cardiac arrest, adrenaline improves survival to hospital admission and to discharge. ( 31108517 )
2019
23
Cardiopulmonary resuscitation with percutaneous ECMO in refractory in-hospital cardiac arrest: a single-center experience. ( 31109789 )
2019
24
Chloral Hydrate Overdose Survived after Cardiac Arrest with Excellent Response to Intravenous β-blocker. ( 31110633 )
2019
25
DISPATCHER-ASSISTED CARDIOPULMONARY RESUSCITATION FOR PAEDIATRIC OUT-OF-HOSPITAL CARDIAC ARREST: A STRUCTURED EVALUATION OF COMMUNICATION ISSUES USING THE SACCIA® SAFE COMMUNICATION TYPOLOGY. ( 30999084 )
2019
26
Utility and Challenges of an Early Invasive Strategy in Patients Resuscitated From Out-of-Hospital Cardiac Arrest. ( 31000007 )
2019
27
Hydrocephalus-induced neurogenic stunned myocardium and cardiac arrest in a child: completely reversed with CSF diversion. ( 31003226 )
2019
28
Prehospital determinants of successful resuscitation after traumatic and non-traumatic out-of-hospital cardiac arrest. ( 31003991 )
2019
29
Can cardiac resynchronization therapy be used as a tool to reduce sudden cardiac arrest risk? ( 31004607 )
2019
30
Cardiac arrest due to acute massive aortic root thrombosis after pericardial bioprosthetic aortic valve replacement. ( 31004934 )
2019
31
Capnography: A support tool for the Detection of Return of Spontaneous Circulation in Out-of-Hospital Cardiac Arrest. ( 31005583 )
2019
32
Comparing bystander response to a sudden cardiac arrest using a virtual reality CPR training mobile app versus a standard CPR training mobile app. ( 31005588 )
2019
33
Hippocampus and basal ganglia as potential sentinel sites for ischemic pathology after resuscitated cardiac arrest. ( 31005590 )
2019
34
Nutrition During Targeted Temperature Management After Cardiac Arrest: Observational Study of Neurological Outcomes and Nutrition Tolerance. ( 31006879 )
2019
35
Effect of Endotracheal Intubation and Supraglottic Airway Device Placement during Cardiopulmonary Resuscitation on Carotid Blood Flow over Resuscitation Time: An Experimental Porcine Cardiac Arrest Study. ( 31009692 )
2019
36
Large Urban Center Improves Out-of-Hospital Cardiac Arrest Survival. ( 31009693 )
2019
37
Bradycardia, Hypotension, and Cardiac Arrest: A Complication of Local Anesthetics. ( 31011496 )
2019
38
The incidence of acute kidney injury following cardiac arrest and cardiopulmonary resuscitation in a rat model. ( 31014141 )
2019
39
Resuscitative Thoracotomy for Traumatic Cardiac Arrest: Clinical Evidence and Clinical Governance. ( 31014944 )
2019
40
Serum tau fragments as predictors of death or poor neurological outcome after out-of-hospital cardiac arrest. ( 31017476 )
2019
41
Acute loss of psychic self-activation after cardiac arrest and delayed bilateral pallidal lesions on brain MRI. ( 31020910 )
2019
42
Postresuscitation Care after Out-of-hospital Cardiac Arrest: Clinical Update and Focus on Targeted Temperature Management. ( 31021845 )
2019
43
Cardiac arrest: prediction models in the early phase of hospitalization. ( 31022083 )
2019
44
Assessment of neurocognitive function after cardiac arrest. ( 31022085 )
2019
45
Out-of-hospital cardiac arrest survivors need both cardiological and neurological rehabilitation! ( 31022086 )
2019
46
Change in myocardial function after resuscitated sudden cardiac arrest and its impact on long-term mortality and defibrillator implantation. ( 31022454 )
2019
47
Cut-off values of serum potassium and core temperature at hospital admission for extracorporeal rewarming of avalanche victims in cardiac arrest: A retrospective multi-centre study. ( 31022496 )
2019
48
Usefulness of Neuron Specific Enolase in prognostication after cardiac arrest: impact of age and time to ROSC. ( 31022497 )
2019
49
Burden of Coronary Artery Disease as a Cause of Sudden Cardiac Arrest in the Young. ( 31023437 )
2019
50
Cardiopulmonary resuscitation ameliorates myocardial mitochondrial dysfunction in a cardiac arrest rat model. ( 31027936 )
2019
Sources

Variations for Cardiac Arrest

About this section

ClinVar genetic disease variations for Cardiac Arrest:

6 (show top 50) (show all 70)
# Gene Variation Type Significance SNP ID Assembly Location
1 PLN NM_002667.4(PLN): c.116T> G (p.Leu39Ter) single nucleotide variant Pathogenic/Likely pathogenic rs111033560 GRCh37 Chromosome 6, 118880200: 118880200
2 PLN NM_002667.4(PLN): c.116T> G (p.Leu39Ter) single nucleotide variant Pathogenic/Likely pathogenic rs111033560 GRCh38 Chromosome 6, 118559037: 118559037
3 MYBPC3 NM_000256.3(MYBPC3): c.3392T> C (p.Ile1131Thr) single nucleotide variant Likely benign rs370890951 GRCh37 Chromosome 11, 47354463: 47354463
4 MYBPC3 NM_000256.3(MYBPC3): c.3392T> C (p.Ile1131Thr) single nucleotide variant Likely benign rs370890951 GRCh38 Chromosome 11, 47332912: 47332912
5 DSG2 NM_001943.3(DSG2): c.437G> T (p.Arg146Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs113451409 GRCh37 Chromosome 18, 29101120: 29101120
6 DSG2 NM_001943.3(DSG2): c.437G> T (p.Arg146Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs113451409 GRCh38 Chromosome 18, 31521157: 31521157
7 DSC2 NM_004949.4(DSC2): c.1073C> T (p.Thr358Ile) single nucleotide variant Benign/Likely benign rs139399951 GRCh37 Chromosome 18, 28662896: 28662896
8 DSC2 NM_004949.4(DSC2): c.1073C> T (p.Thr358Ile) single nucleotide variant Benign/Likely benign rs139399951 GRCh38 Chromosome 18, 31082930: 31082930
9 TTN NM_001267550.2(TTN): c.29230C> T (p.Arg9744Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs375266859 GRCh37 Chromosome 2, 179571371: 179571371
10 TTN NM_001267550.2(TTN): c.29230C> T (p.Arg9744Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs375266859 GRCh38 Chromosome 2, 178706644: 178706644
11 SCN5A NM_198056.2(SCN5A): c.1715C> A (p.Ala572Asp) single nucleotide variant Benign/Likely benign rs36210423 GRCh37 Chromosome 3, 38645378: 38645378
12 SCN5A NM_198056.2(SCN5A): c.1715C> A (p.Ala572Asp) single nucleotide variant Benign/Likely benign rs36210423 GRCh38 Chromosome 3, 38603887: 38603887
13 AKAP9 NM_005751.4(AKAP9): c.11378C> G (p.Ser3793Cys) single nucleotide variant Uncertain significance rs730880044 GRCh38 Chromosome 7, 92105725: 92105725
14 AKAP9 NM_005751.4(AKAP9): c.11378C> G (p.Ser3793Cys) single nucleotide variant Uncertain significance rs730880044 GRCh37 Chromosome 7, 91735039: 91735039
15 RYR2 NM_001035.2(RYR2): c.13759A> C (p.Ile4587Leu) single nucleotide variant Uncertain significance rs730880198 GRCh37 Chromosome 1, 237955600: 237955600
16 RYR2 NM_001035.2(RYR2): c.13759A> C (p.Ile4587Leu) single nucleotide variant Uncertain significance rs730880198 GRCh38 Chromosome 1, 237792300: 237792300
17 ANK2 NM_001148.4(ANK2): c.6206G> A (p.Arg2069His) single nucleotide variant Likely benign rs149645600 GRCh37 Chromosome 4, 114275980: 114275980
18 ANK2 NM_001148.4(ANK2): c.6206G> A (p.Arg2069His) single nucleotide variant Likely benign rs149645600 GRCh38 Chromosome 4, 113354824: 113354824
19 DSP NM_004415.3(DSP): c.2260G> A (p.Glu754Lys) single nucleotide variant Uncertain significance rs730880080 GRCh37 Chromosome 6, 7574448: 7574448
20 DSP NM_004415.3(DSP): c.2260G> A (p.Glu754Lys) single nucleotide variant Uncertain significance rs730880080 GRCh38 Chromosome 6, 7574215: 7574215
21 DSP NM_004415.2(DSP): c.2821C> T (p.Arg941Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730880082 GRCh38 Chromosome 6, 7576986: 7576986
22 DSP NM_004415.2(DSP): c.2821C> T (p.Arg941Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730880082 GRCh37 Chromosome 6, 7577219: 7577219
23 CACNA2D1 NM_000722.3(CACNA2D1): c.2264G> C (p.Ser755Thr) single nucleotide variant Benign/Likely benign rs151327713 GRCh38 Chromosome 7, 81969925: 81969925
24 CACNA2D1 NM_000722.3(CACNA2D1): c.2264G> C (p.Ser755Thr) single nucleotide variant Benign/Likely benign rs151327713 GRCh37 Chromosome 7, 81599241: 81599241
25 AKAP9 NM_005751.4(AKAP9): c.1099G> A (p.Val367Met) single nucleotide variant Likely benign rs138161478 GRCh37 Chromosome 7, 91630330: 91630330
26 AKAP9 NM_005751.4(AKAP9): c.1099G> A (p.Val367Met) single nucleotide variant Likely benign rs138161478 GRCh38 Chromosome 7, 92001016: 92001016
27 CACNB2 NM_201571.3(CACNB2): c.1122+3A> T single nucleotide variant Uncertain significance rs200174877 GRCh37 Chromosome 10, 18823159: 18823159
28 CACNB2 NM_201571.3(CACNB2): c.1122+3A> T single nucleotide variant Uncertain significance rs200174877 GRCh38 Chromosome 10, 18534230: 18534230
29 CACNB2 NM_201571.3(CACNB2): c.1558G> A (p.Gly520Ser) single nucleotide variant Likely pathogenic rs730880059 GRCh37 Chromosome 10, 18828312: 18828312
30 CACNB2 NM_201571.3(CACNB2): c.1558G> A (p.Gly520Ser) single nucleotide variant Likely pathogenic rs730880059 GRCh38 Chromosome 10, 18539383: 18539383
31 MYH6 NM_002471.3(MYH6): c.4713G> T (p.Lys1571Asn) single nucleotide variant Uncertain significance rs730880151 GRCh37 Chromosome 14, 23855770: 23855770
32 MYH6 NM_002471.3(MYH6): c.4713G> T (p.Lys1571Asn) single nucleotide variant Uncertain significance rs730880151 GRCh38 Chromosome 14, 23386561: 23386561
33 DSG2 NM_001943.4(DSG2): c.1063G> A (p.Ala355Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs201046640 GRCh37 Chromosome 18, 29110998: 29110998
34 DSG2 NM_001943.4(DSG2): c.1063G> A (p.Ala355Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs201046640 GRCh38 Chromosome 18, 31531035: 31531035
35 RYR2 NM_001035.2(RYR2): c.378T> A (p.Ser126Arg) single nucleotide variant Uncertain significance rs869025507 GRCh37 Chromosome 1, 237532902: 237532902
36 RYR2 NM_001035.2(RYR2): c.378T> A (p.Ser126Arg) single nucleotide variant Uncertain significance rs869025507 GRCh38 Chromosome 1, 237369602: 237369602
37 SCN5A NM_001099404.1(SCN5A): c.5075T> C (p.Phe1692Ser) single nucleotide variant Uncertain significance rs869025521 GRCh37 Chromosome 3, 38592788: 38592788
38 SCN5A NM_001099404.1(SCN5A): c.5075T> C (p.Phe1692Ser) single nucleotide variant Uncertain significance rs869025521 GRCh38 Chromosome 3, 38551297: 38551297
39 SCN5A NM_198056.2(SCN5A): c.559A> G (p.Thr187Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs869025517 GRCh38 Chromosome 3, 38620895: 38620895
40 SCN5A NM_198056.2(SCN5A): c.559A> G (p.Thr187Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs869025517 GRCh37 Chromosome 3, 38662386: 38662386
41 SLMAP NM_007159.4(SLMAP): c.1918+1G> A single nucleotide variant Uncertain significance rs869025527 GRCh38 Chromosome 3, 57912702: 57912702
42 SLMAP NM_007159.4(SLMAP): c.1918+1G> A single nucleotide variant Uncertain significance rs869025527 GRCh37 Chromosome 3, 57898429: 57898429
43 ANK2 NM_001148.4(ANK2): c.5509G> A (p.Ala1837Thr) single nucleotide variant Uncertain significance rs199527708 GRCh37 Chromosome 4, 114275283: 114275283
44 ANK2 NM_001148.4(ANK2): c.5509G> A (p.Ala1837Thr) single nucleotide variant Uncertain significance rs199527708 GRCh38 Chromosome 4, 113354127: 113354127
45 ANK2 NM_001148.4(ANK2): c.7458C> G (p.His2486Gln) single nucleotide variant Uncertain significance rs776972443 GRCh37 Chromosome 4, 114277232: 114277232
46 ANK2 NM_001148.4(ANK2): c.7458C> G (p.His2486Gln) single nucleotide variant Uncertain significance rs776972443 GRCh38 Chromosome 4, 113356076: 113356076
47 ANK2 NM_001148.4(ANK2): c.7577C> T (p.Ser2526Leu) single nucleotide variant Uncertain significance rs762909298 GRCh37 Chromosome 4, 114277351: 114277351
48 ANK2 NM_001148.4(ANK2): c.7577C> T (p.Ser2526Leu) single nucleotide variant Uncertain significance rs762909298 GRCh38 Chromosome 4, 113356195: 113356195
49 DSP NM_004415.3(DSP): c.2047G> A (p.Glu683Lys) single nucleotide variant Uncertain significance rs775181391 GRCh37 Chromosome 6, 7572218: 7572218
50 DSP NM_004415.3(DSP): c.2047G> A (p.Glu683Lys) single nucleotide variant Uncertain significance rs775181391 GRCh38 Chromosome 6, 7571985: 7571985
Sources

Expression for Cardiac Arrest

About this section
Search GEO for disease gene expression data for Cardiac Arrest.
Sources

Pathways for Cardiac Arrest

About this section

Pathways related to Cardiac Arrest according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds 67
Show member pathways
 13.22 ALB AVP CALM1 CALM3 PLN RYR2
2
Aldosterone synthesis and secretion 38
Show member pathways
 12.62 ALB CALM1 CALM3 KCNQ1 PLN RYR2
3
Neuroscience 4
12.41 AVP CALM1 ENO2 S100B SCN5A
4
Ion channel transport 67
Show member pathways
 12.35 CALM1 CALM3 PLN RYR2 TRDN
5
Cardiac conduction 67
Show member pathways
 12.34 CALM1 CALM3 KCNQ1 MYBPC3 PLN RYR2
6
DREAM Repression and Dynorphin Expression 65
Show member pathways
 12.33 CALM1 CALM3 CYCS RYR2
7
Myometrial Relaxation and Contraction Pathways 1
Show member pathways
 12.32 CALM1 CALM3 CASQ2 PLN RYR2
8
cAMP signaling pathway 38
12.15 CALM1 CALM3 PLN RYR2
9
Calcium signaling pathway 38
Show member pathways
 12.09 CALM1 CALM3 PLN RYR2
10
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.01 AVP KCNQ1 RYR2 SCN5A
11
Dilated cardiomyopathy (DCM) 38
Show member pathways
 11.9 ACE MYBPC3 PLN RYR2 TNNT2
12
Ca, cAMP and Lipid Signaling 4
11.77 ALB CALM1 PLN S100B
13
Renin secretion 38
11.55 ACE CALM1 CALM3
14
Phase 0 - rapid depolarisation 67
Show member pathways
 11.5 CALM1 CALM3 KCNQ1 SCN5A
15
Nur77 Signaling in T-Cell 65
11.12 CALM1 CALM3 CYCS
16
Antiarrhythmic Pathway, Pharmacodynamics 62
10.85 CASQ2 DSP KCNQ1 PLN RYR2 SCN5A
17
RHO GTPases activate IQGAPs 67
10.67 CALM1 CALM3
Sources

GO Terms for Cardiac Arrest

About this section

Cellular components related to Cardiac Arrest according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 Z disc GO:0030018 9.71 CASQ2 MYBPC3 RYR2 SCN5A
2 sarcoplasmic reticulum GO:0016529 9.67